Men's Health

Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478


BACKGROUND: The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).

OBJECTIVE: We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.

Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.


Abstract not available at this time.

Czeizel AE, Rothman KJ. Does relaxed reproductive selection explain the decline in male reproductive health? A new hypothesis. Letter to Edtior. Epidemiology. 2002 Jan;13(1):113-4.


Abstract not available at this time.

 

Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of proton therapy in the treatment of localized prostate cancer. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 May 20; 30(15):e15184.

Background: Proton therapy (PT) has received much public attention due to its higher costs and lack of evidence of clinical benefit compared to intensity modulated radiation therapy (IMRT) for prostate cancer treatment. In this economic study, we performed a threshold analysis to assess the reduction in toxicity that PT would need to achieve compared with IMRT to be considered cost-effective for the treatment of localized prostate cancer.

Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O'Malley CD. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporosis. 2014;9(1):182. doi: 10.1007/s11657-014-0182-3

In nine industrialized countries in North America, Europe, Japan, and Australia, country-specific osteoporosis prevalence (estimated from published data) at the total hip or hip/spine ranged from 9 to 38 % for women and 1 to 8 % for men. In these countries, osteoporosis affects up to 49 million individuals.

PURPOSE: Standardized country-specific prevalence estimates are scarce, limiting our ability to anticipate the potential global impact of osteoporosis.

DeMuro-Mercon CJ, Goldstone SE, Huyett JW, Santanello N, Mast TC. Developing a new measure to assess the psychosocial impact and burden of hpv illness on men who have sex with men (MSM). Poster presented at the Papillomavirus 21st International Conference and Clinical Workshop; 2004.

Abstract not available at this time

Wincze J, Rosen R, Korenman S, Niederberger C, Sadovsky R, McLeod LD. Development and initial evaluation of the erection quality scale. Presented at the Sexual Medicine Society of North America (SMS) Fifth Annual Research Meeting; October 2003.

Abstract not available at this time

Britt D, Kubin M, Keininger D, Trudeau E, Sagnier P, Beneke M. Development and validation of the treatment satisfaction scale (TSS) for erectile dysfunction. J Sex Med. 2003 Oct;25(Suppl 5):S180.

No abstract available at this time.

Britt D, Kubin M, Keininger D, Trudeau E, Sagnier P, Fugl-Meyer A. Development and validation of the treatment satisfaction scale (TSS) for erectile dysfunction. Pharmacotherapy. 2003 Jun;23(10):132.


Abstract not available at this time.

Kubin M, Britt D, Trudeau E, Fugl-Meyer A, Gondek K. Patient and partner treatment satisfaction scale (TSS) in erectile dysfunction. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 2003. Barcelona, Spain.


Abstract not available at this time.

Subscribe to Men's Health

How Can We Help You?